基于药物基因组学的质子泵抑制剂个体化精准治疗分析

Analysis of individualized precision treatment of proton pump inhibitors based on pharmacogenomics

目的:探讨CYP2C19基因型对质子泵抑制剂(proton pump inhibitor,PPI)个体化治疗的影响,为临床个体化精准用药提供有益参考。方法:查阅国内外权威指南及最新研究等相关文献,就CYP2C19基因多态性对PPI代谢与治疗的影响及基于药物基因组学的剂量建议进行综述与分析。结果:CYP2C19基因多态性与PPI抑酸治疗效果、安全性具有相关性,在临床治疗中根据患者(尤其是特殊群体)CYP2C19表型进行PPI个体化治疗有助于提升疗效与安全性。结论:基于药物基因组学的PPI个体化应用或可为临床治疗提供新的思路,进一步促进临床用药的合理性与精细化。

OBJECTIVE This study aimed to explore the influence of CYP2 C19 genotype on PPI individualized treatment and provide useful reference for clinical individualized and accurate medication.METHODS By consulting authoritative guidelines,the latest frontier research and other relevant literature,The effects of CYP2 C19 gene polymorphism on PPI metabolism and treatment and dose recommendations based on pharmacogenomics were reviewed and analyzed.RESULTS CYP2 C19 gene polymorphism is related to the efficacy and safety of PPI acid inhibition therapy,in clinical treatment,PPI individualized treatment according to the CYP2 C19 phenotype of patients(especially special groups)contribute to the efficacy and safety for patients.CONCLUSION PPI treatment based on pharmacogenomics may provide new ideas for clinical treatment and further promote the rationality and refinement of clinical medication.